| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glutathione | 36 | 2021 | 343 | 5.730 |
Why?
|
| Glutathione Transferase | 18 | 2021 | 166 | 3.270 |
Why?
|
| Antineoplastic Agents | 25 | 2022 | 1070 | 3.040 |
Why?
|
| Glutathione S-Transferase pi | 11 | 2021 | 53 | 2.710 |
Why?
|
| Cisplatin | 13 | 2021 | 192 | 2.620 |
Why?
|
| Oxidative Stress | 27 | 2021 | 718 | 2.430 |
Why?
|
| Neoplasms | 24 | 2022 | 1667 | 2.110 |
Why?
|
| Protein Processing, Post-Translational | 12 | 2019 | 284 | 1.510 |
Why?
|
| Glutathione Disulfide | 7 | 2014 | 31 | 1.490 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2020 | 332 | 1.420 |
Why?
|
| Oxidation-Reduction | 26 | 2021 | 567 | 1.380 |
Why?
|
| Protein Disulfide-Isomerases | 6 | 2019 | 27 | 1.220 |
Why?
|
| Signal Transduction | 14 | 2018 | 2689 | 1.160 |
Why?
|
| Prodrugs | 7 | 2016 | 54 | 1.150 |
Why?
|
| Azo Compounds | 8 | 2010 | 33 | 1.000 |
Why?
|
| Nitric Oxide | 9 | 2021 | 382 | 0.960 |
Why?
|
| Animals | 64 | 2022 | 20881 | 0.930 |
Why?
|
| Reactive Oxygen Species | 16 | 2020 | 499 | 0.920 |
Why?
|
| para-Aminobenzoates | 8 | 2010 | 27 | 0.890 |
Why?
|
| Cysteine | 8 | 2018 | 112 | 0.820 |
Why?
|
| Kidney Diseases | 4 | 2009 | 307 | 0.770 |
Why?
|
| Bortezomib | 1 | 2020 | 45 | 0.720 |
Why?
|
| ATP-Binding Cassette Transporters | 7 | 2012 | 120 | 0.700 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 92 | 0.680 |
Why?
|
| Humans | 83 | 2022 | 68618 | 0.670 |
Why?
|
| Gene Expression Regulation, Enzymologic | 4 | 2014 | 282 | 0.650 |
Why?
|
| Isoflavones | 4 | 2020 | 31 | 0.640 |
Why?
|
| Cell Survival | 8 | 2019 | 901 | 0.620 |
Why?
|
| Aminobutyrates | 2 | 2020 | 94 | 0.610 |
Why?
|
| Unfolded Protein Response | 6 | 2021 | 70 | 0.610 |
Why?
|
| Cell Line, Tumor | 22 | 2021 | 1851 | 0.600 |
Why?
|
| Mice | 31 | 2019 | 8474 | 0.590 |
Why?
|
| Carrier Proteins | 1 | 2020 | 597 | 0.580 |
Why?
|
| Estrogen Receptor alpha | 1 | 2018 | 65 | 0.580 |
Why?
|
| Radiopharmaceuticals | 4 | 2019 | 114 | 0.580 |
Why?
|
| Nanoparticles | 4 | 2021 | 254 | 0.540 |
Why?
|
| Dendritic Cells | 1 | 2018 | 201 | 0.540 |
Why?
|
| Drug Carriers | 4 | 2021 | 90 | 0.520 |
Why?
|
| Breast Neoplasms | 7 | 2020 | 1536 | 0.520 |
Why?
|
| Kidney Tubules, Proximal | 3 | 2009 | 81 | 0.520 |
Why?
|
| Doxorubicin | 5 | 2019 | 231 | 0.510 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2020 | 38 | 0.510 |
Why?
|
| Cell Death | 3 | 2018 | 329 | 0.500 |
Why?
|
| gamma-Glutamyltransferase | 6 | 2009 | 37 | 0.500 |
Why?
|
| Folic Acid | 3 | 2021 | 123 | 0.490 |
Why?
|
| Proteins | 3 | 2014 | 474 | 0.470 |
Why?
|
| 4-Aminobenzoic Acid | 9 | 2021 | 30 | 0.470 |
Why?
|
| Drug Discovery | 2 | 2016 | 94 | 0.470 |
Why?
|
| Drug Combinations | 8 | 2020 | 304 | 0.470 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2019 | 81 | 0.460 |
Why?
|
| Alanine | 1 | 2014 | 38 | 0.460 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2014 | 756 | 0.440 |
Why?
|
| Stress, Physiological | 2 | 2011 | 215 | 0.410 |
Why?
|
| Mice, Knockout | 10 | 2018 | 1692 | 0.390 |
Why?
|
| Antioxidants | 2 | 2021 | 304 | 0.380 |
Why?
|
| Mitochondria | 6 | 2019 | 643 | 0.380 |
Why?
|
| Reactive Nitrogen Species | 1 | 2011 | 32 | 0.370 |
Why?
|
| Carbon-Sulfur Lyases | 4 | 2008 | 6 | 0.360 |
Why?
|
| Obstetric Labor Complications | 1 | 2010 | 20 | 0.360 |
Why?
|
| Technetium | 3 | 2019 | 38 | 0.350 |
Why?
|
| Chorioamnionitis | 1 | 2010 | 40 | 0.350 |
Why?
|
| Hypertension | 5 | 2020 | 1535 | 0.340 |
Why?
|
| Fever | 1 | 2010 | 96 | 0.340 |
Why?
|
| Drug Delivery Systems | 4 | 2019 | 236 | 0.340 |
Why?
|
| Mice, Inbred BALB C | 9 | 2021 | 532 | 0.330 |
Why?
|
| Substance-Related Disorders | 2 | 2018 | 1242 | 0.330 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2020 | 88 | 0.320 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2005 | 82 | 0.320 |
Why?
|
| Molecular Mimicry | 1 | 2008 | 13 | 0.320 |
Why?
|
| Oxidoreductases | 2 | 2006 | 117 | 0.310 |
Why?
|
| Endoplasmic Reticulum | 4 | 2017 | 148 | 0.310 |
Why?
|
| Lipids | 2 | 2021 | 298 | 0.310 |
Why?
|
| Cell Physiological Phenomena | 1 | 2008 | 19 | 0.310 |
Why?
|
| Protein Kinases | 2 | 2007 | 122 | 0.310 |
Why?
|
| Lung Neoplasms | 5 | 2019 | 1173 | 0.300 |
Why?
|
| Kidney | 4 | 2021 | 945 | 0.300 |
Why?
|
| Tissue Distribution | 8 | 2019 | 282 | 0.290 |
Why?
|
| Pregnancy Complications | 1 | 2010 | 286 | 0.290 |
Why?
|
| Paclitaxel | 2 | 2017 | 140 | 0.280 |
Why?
|
| Cytotoxins | 2 | 2005 | 23 | 0.270 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2019 | 201 | 0.270 |
Why?
|
| Hyperglycemia | 2 | 2019 | 158 | 0.270 |
Why?
|
| Endoplasmic Reticulum Stress | 4 | 2019 | 99 | 0.270 |
Why?
|
| Cell Differentiation | 3 | 2018 | 1034 | 0.270 |
Why?
|
| Mice, Inbred C57BL | 6 | 2018 | 2791 | 0.270 |
Why?
|
| Isoenzymes | 3 | 2005 | 308 | 0.260 |
Why?
|
| Ovarian Neoplasms | 2 | 2009 | 267 | 0.260 |
Why?
|
| Enzyme Inhibitors | 4 | 2019 | 659 | 0.250 |
Why?
|
| Acetylcysteine | 3 | 2018 | 296 | 0.250 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2020 | 163 | 0.250 |
Why?
|
| Nitroso Compounds | 1 | 2004 | 16 | 0.250 |
Why?
|
| Protein Folding | 3 | 2009 | 82 | 0.240 |
Why?
|
| Cell Proliferation | 5 | 2018 | 1174 | 0.240 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 4 | 2010 | 140 | 0.240 |
Why?
|
| Female | 24 | 2020 | 38074 | 0.240 |
Why?
|
| Methionine | 1 | 2004 | 36 | 0.230 |
Why?
|
| Estrogens | 2 | 2016 | 173 | 0.220 |
Why?
|
| Disease | 1 | 2003 | 41 | 0.220 |
Why?
|
| Liver Neoplasms | 2 | 2020 | 334 | 0.220 |
Why?
|
| Molecular Structure | 3 | 2011 | 397 | 0.210 |
Why?
|
| Plant Extracts | 2 | 2021 | 122 | 0.210 |
Why?
|
| Neoplasm Proteins | 3 | 2013 | 307 | 0.210 |
Why?
|
| Prostatic Neoplasms | 3 | 2019 | 778 | 0.210 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2012 | 300 | 0.210 |
Why?
|
| Down Syndrome | 1 | 2004 | 120 | 0.210 |
Why?
|
| DNA Helicases | 1 | 2002 | 64 | 0.210 |
Why?
|
| Bone Marrow | 2 | 2014 | 168 | 0.200 |
Why?
|
| Depsipeptides | 1 | 2022 | 21 | 0.200 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2019 | 268 | 0.200 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2021 | 8 | 0.200 |
Why?
|
| HL-60 Cells | 3 | 2010 | 50 | 0.200 |
Why?
|
| Genetic Variation | 1 | 2003 | 220 | 0.200 |
Why?
|
| Fabaceae | 1 | 2021 | 12 | 0.200 |
Why?
|
| Phytochemicals | 1 | 2021 | 6 | 0.200 |
Why?
|
| Nitric Oxide Synthase | 2 | 2014 | 163 | 0.200 |
Why?
|
| Plant Oils | 1 | 2021 | 31 | 0.200 |
Why?
|
| Serpins | 3 | 2019 | 205 | 0.200 |
Why?
|
| Cell Movement | 3 | 2014 | 630 | 0.200 |
Why?
|
| Actins | 3 | 2019 | 249 | 0.190 |
Why?
|
| Plants, Medicinal | 1 | 2021 | 43 | 0.190 |
Why?
|
| Ligands | 2 | 2014 | 317 | 0.190 |
Why?
|
| Inflammation | 2 | 2019 | 1030 | 0.190 |
Why?
|
| Blood Glucose | 3 | 2019 | 631 | 0.190 |
Why?
|
| Naphthoquinones | 1 | 2020 | 14 | 0.190 |
Why?
|
| Lung | 2 | 2016 | 849 | 0.190 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2020 | 9 | 0.190 |
Why?
|
| Oxidoreductases Acting on Sulfur Group Donors | 3 | 2012 | 20 | 0.190 |
Why?
|
| Polyethylene Glycols | 2 | 2019 | 149 | 0.190 |
Why?
|
| Drug Liberation | 4 | 2021 | 17 | 0.180 |
Why?
|
| Voltage-Dependent Anion Channel 2 | 1 | 2020 | 9 | 0.180 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2020 | 36 | 0.180 |
Why?
|
| Voltage-Dependent Anion Channel 1 | 1 | 2020 | 10 | 0.180 |
Why?
|
| Models, Biological | 4 | 2016 | 981 | 0.180 |
Why?
|
| Glutaredoxins | 3 | 2016 | 12 | 0.180 |
Why?
|
| Valsartan | 1 | 2020 | 99 | 0.180 |
Why?
|
| Immunoglobulins | 1 | 2020 | 97 | 0.180 |
Why?
|
| Models, Molecular | 3 | 2012 | 546 | 0.180 |
Why?
|
| Down-Regulation | 3 | 2011 | 447 | 0.180 |
Why?
|
| Hematopoiesis | 2 | 2018 | 108 | 0.180 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 271 | 0.170 |
Why?
|
| Perindopril | 1 | 2019 | 4 | 0.170 |
Why?
|
| Indapamide | 1 | 2019 | 3 | 0.170 |
Why?
|
| Amlodipine | 1 | 2019 | 31 | 0.170 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 184 | 0.170 |
Why?
|
| Male | 21 | 2020 | 37321 | 0.170 |
Why?
|
| Radioisotope Renography | 1 | 2019 | 2 | 0.170 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2019 | 16 | 0.170 |
Why?
|
| Diuresis | 1 | 2019 | 20 | 0.170 |
Why?
|
| Estramustine | 2 | 2012 | 35 | 0.170 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2019 | 48 | 0.170 |
Why?
|
| Ureteral Obstruction | 1 | 2019 | 25 | 0.170 |
Why?
|
| Apoptosis | 6 | 2020 | 1641 | 0.170 |
Why?
|
| Radiation-Protective Agents | 1 | 2019 | 16 | 0.170 |
Why?
|
| Benzene Derivatives | 1 | 2019 | 12 | 0.170 |
Why?
|
| Heme Oxygenase-1 | 1 | 2019 | 40 | 0.170 |
Why?
|
| Organoselenium Compounds | 1 | 2019 | 17 | 0.170 |
Why?
|
| Positron-Emission Tomography | 2 | 2017 | 160 | 0.170 |
Why?
|
| Homeostasis | 3 | 2021 | 291 | 0.170 |
Why?
|
| Gamma Rays | 1 | 2019 | 64 | 0.170 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2019 | 31 | 0.160 |
Why?
|
| Outpatients | 1 | 2019 | 127 | 0.160 |
Why?
|
| Liposomes | 4 | 2021 | 107 | 0.160 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2019 | 140 | 0.160 |
Why?
|
| Ubiquinone | 1 | 2018 | 14 | 0.160 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 132 | 0.160 |
Why?
|
| Docosahexaenoic Acids | 1 | 2018 | 12 | 0.160 |
Why?
|
| Theranostic Nanomedicine | 1 | 2018 | 6 | 0.160 |
Why?
|
| alpha-Tocopherol | 1 | 2018 | 5 | 0.160 |
Why?
|
| Diagnostic Imaging | 2 | 2017 | 201 | 0.160 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 84 | 0.160 |
Why?
|
| Diet, Mediterranean | 1 | 2018 | 12 | 0.160 |
Why?
|
| Cellular Senescence | 1 | 2019 | 112 | 0.160 |
Why?
|
| Fatty Liver | 1 | 2019 | 97 | 0.160 |
Why?
|
| Energy Metabolism | 2 | 2019 | 222 | 0.160 |
Why?
|
| Mutation, Missense | 1 | 2019 | 112 | 0.150 |
Why?
|
| Cells, Cultured | 5 | 2011 | 2673 | 0.150 |
Why?
|
| Amino Acid Sequence | 3 | 2009 | 1083 | 0.150 |
Why?
|
| Inactivation, Metabolic | 2 | 2011 | 28 | 0.150 |
Why?
|
| Lovastatin | 1 | 2018 | 78 | 0.150 |
Why?
|
| Hypercholesterolemia | 1 | 2018 | 86 | 0.150 |
Why?
|
| Stroke Volume | 1 | 2020 | 586 | 0.150 |
Why?
|
| Molecular Sequence Data | 3 | 2009 | 1447 | 0.150 |
Why?
|
| Hemoglobins | 1 | 2018 | 120 | 0.150 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2017 | 3 | 0.150 |
Why?
|
| Chorioallantoic Membrane | 1 | 2017 | 3 | 0.150 |
Why?
|
| Parathyroid Neoplasms | 1 | 2017 | 13 | 0.150 |
Why?
|
| Polyglycolic Acid | 1 | 2017 | 20 | 0.150 |
Why?
|
| Brain | 2 | 2019 | 2176 | 0.150 |
Why?
|
| Guanidines | 1 | 2017 | 32 | 0.150 |
Why?
|
| Fumarates | 1 | 2017 | 28 | 0.140 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2017 | 45 | 0.140 |
Why?
|
| Bombesin | 1 | 2016 | 4 | 0.140 |
Why?
|
| Nanostructures | 1 | 2018 | 112 | 0.140 |
Why?
|
| Drug Compounding | 3 | 2021 | 34 | 0.140 |
Why?
|
| Radioisotopes | 1 | 2017 | 40 | 0.140 |
Why?
|
| Hyperuricemia | 1 | 2016 | 13 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 64 | 0.140 |
Why?
|
| Dextran Sulfate | 1 | 2017 | 88 | 0.140 |
Why?
|
| Disease Models, Animal | 6 | 2019 | 2550 | 0.140 |
Why?
|
| Adipocytes | 1 | 2017 | 88 | 0.140 |
Why?
|
| Sulfhydryl Compounds | 3 | 2013 | 73 | 0.140 |
Why?
|
| Lactic Acid | 1 | 2017 | 86 | 0.140 |
Why?
|
| Drug-Seeking Behavior | 1 | 2019 | 213 | 0.140 |
Why?
|
| Biomarkers | 2 | 2019 | 1593 | 0.140 |
Why?
|
| Up-Regulation | 3 | 2019 | 682 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2017 | 124 | 0.140 |
Why?
|
| Protein S | 1 | 2016 | 9 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 561 | 0.140 |
Why?
|
| Catalytic Domain | 2 | 2009 | 99 | 0.130 |
Why?
|
| Antihypertensive Agents | 2 | 2017 | 498 | 0.130 |
Why?
|
| I-kappa B Kinase | 1 | 2016 | 40 | 0.130 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2017 | 155 | 0.130 |
Why?
|
| Metabolic Syndrome | 1 | 2018 | 191 | 0.130 |
Why?
|
| Nucleus Accumbens | 1 | 2019 | 417 | 0.130 |
Why?
|
| Free Radicals | 1 | 2016 | 65 | 0.130 |
Why?
|
| NF-kappa B | 2 | 2016 | 432 | 0.130 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 68 | 0.130 |
Why?
|
| Tumor Burden | 3 | 2021 | 132 | 0.130 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 597 | 0.130 |
Why?
|
| Respiratory Mucosa | 1 | 2016 | 52 | 0.130 |
Why?
|
| Membrane Potential, Mitochondrial | 2 | 2020 | 93 | 0.130 |
Why?
|
| Colitis | 1 | 2017 | 156 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2019 | 326 | 0.130 |
Why?
|
| Nitric Oxide Synthase Type III | 3 | 2012 | 102 | 0.130 |
Why?
|
| Stem Cells | 1 | 2016 | 248 | 0.120 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2017 | 195 | 0.120 |
Why?
|
| Sphingosine | 1 | 2017 | 315 | 0.120 |
Why?
|
| Cell Line | 5 | 2019 | 1752 | 0.120 |
Why?
|
| Polymers | 1 | 2017 | 244 | 0.120 |
Why?
|
| Liver | 2 | 2017 | 1118 | 0.120 |
Why?
|
| NF-E2-Related Factor 2 | 3 | 2021 | 110 | 0.120 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2021 | 618 | 0.120 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 65 | 0.120 |
Why?
|
| Deoxycytidine | 1 | 2014 | 83 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 627 | 0.120 |
Why?
|
| Zebrafish | 3 | 2021 | 187 | 0.120 |
Why?
|
| Enzyme Activation | 3 | 2005 | 791 | 0.120 |
Why?
|
| Peroxiredoxins | 1 | 2014 | 34 | 0.120 |
Why?
|
| Enzymes | 1 | 2014 | 25 | 0.120 |
Why?
|
| Lens, Crystalline | 1 | 2014 | 39 | 0.110 |
Why?
|
| Drug Stability | 3 | 2021 | 71 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2017 | 1745 | 0.110 |
Why?
|
| LLC-PK1 Cells | 2 | 2003 | 4 | 0.110 |
Why?
|
| Piperazines | 2 | 2013 | 206 | 0.110 |
Why?
|
| Phosphorylation | 2 | 2007 | 1200 | 0.110 |
Why?
|
| Transcription Factors | 1 | 2017 | 753 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 207 | 0.110 |
Why?
|
| Tubulin | 1 | 2013 | 60 | 0.110 |
Why?
|
| Voltage-Dependent Anion Channels | 1 | 2013 | 40 | 0.110 |
Why?
|
| Alleles | 1 | 2014 | 386 | 0.110 |
Why?
|
| Nonmuscle Myosin Type IIA | 1 | 2012 | 4 | 0.110 |
Why?
|
| Platinum | 2 | 2003 | 17 | 0.110 |
Why?
|
| Mucositis | 1 | 2012 | 9 | 0.100 |
Why?
|
| S100 Proteins | 1 | 2012 | 42 | 0.100 |
Why?
|
| Mitochondrial Proteins | 1 | 2013 | 113 | 0.100 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2012 | 22 | 0.100 |
Why?
|
| alpha 1-Antichymotrypsin | 1 | 2012 | 7 | 0.100 |
Why?
|
| Penis | 1 | 2012 | 25 | 0.100 |
Why?
|
| Biotransformation | 3 | 2012 | 69 | 0.100 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2003 | 381 | 0.100 |
Why?
|
| Asthma | 1 | 2016 | 345 | 0.100 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2012 | 306 | 0.100 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2012 | 61 | 0.100 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2011 | 59 | 0.100 |
Why?
|
| Cocaine | 2 | 2019 | 555 | 0.100 |
Why?
|
| Drosophila Proteins | 1 | 2011 | 44 | 0.100 |
Why?
|
| Heart Failure | 1 | 2020 | 1180 | 0.100 |
Why?
|
| Swine | 2 | 2003 | 672 | 0.100 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2011 | 115 | 0.100 |
Why?
|
| Calcium | 2 | 2016 | 929 | 0.090 |
Why?
|
| Structure-Activity Relationship | 2 | 2009 | 420 | 0.090 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 50 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 332 | 0.090 |
Why?
|
| Peptides | 1 | 2014 | 455 | 0.090 |
Why?
|
| Immune System | 1 | 2010 | 63 | 0.090 |
Why?
|
| Labor Stage, First | 1 | 2010 | 5 | 0.090 |
Why?
|
| HLA-B35 Antigen | 1 | 2010 | 6 | 0.090 |
Why?
|
| Protective Agents | 1 | 2010 | 36 | 0.090 |
Why?
|
| Seizures, Febrile | 1 | 2010 | 10 | 0.090 |
Why?
|
| Cell Shape | 1 | 2010 | 37 | 0.090 |
Why?
|
| Drug Resistance | 1 | 2011 | 223 | 0.090 |
Why?
|
| Seizures | 1 | 2012 | 279 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 142 | 0.090 |
Why?
|
| Sex Factors | 2 | 2016 | 1266 | 0.090 |
Why?
|
| Hydrogen Peroxide | 3 | 2019 | 168 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2011 | 290 | 0.090 |
Why?
|
| Protein Binding | 3 | 2021 | 1027 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1851 | 0.080 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2006 | 13 | 0.080 |
Why?
|
| Zebrafish Proteins | 2 | 2021 | 100 | 0.080 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2010 | 91 | 0.080 |
Why?
|
| Aged | 6 | 2020 | 14862 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 370 | 0.080 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2006 | 56 | 0.080 |
Why?
|
| Creatinine | 1 | 2009 | 243 | 0.080 |
Why?
|
| Endothelin-1 | 1 | 2010 | 122 | 0.080 |
Why?
|
| Time Factors | 3 | 2021 | 4655 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 567 | 0.080 |
Why?
|
| Nitric Oxide Donors | 2 | 2010 | 54 | 0.080 |
Why?
|
| Membrane Proteins | 2 | 2010 | 617 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2009 | 194 | 0.080 |
Why?
|
| Neuronal Plasticity | 1 | 2011 | 274 | 0.080 |
Why?
|
| Drug Tolerance | 1 | 2008 | 80 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2012 | 508 | 0.080 |
Why?
|
| Middle Aged | 7 | 2020 | 21147 | 0.080 |
Why?
|
| Body Weight | 2 | 2018 | 554 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 371 | 0.080 |
Why?
|
| Motor Activity | 1 | 2011 | 621 | 0.080 |
Why?
|
| Static Electricity | 2 | 2018 | 91 | 0.080 |
Why?
|
| Particle Size | 2 | 2018 | 201 | 0.070 |
Why?
|
| MCF-7 Cells | 2 | 2019 | 80 | 0.070 |
Why?
|
| Autophagy | 1 | 2009 | 208 | 0.070 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2019 | 89 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2010 | 475 | 0.070 |
Why?
|
| Blood Pressure | 3 | 2019 | 1451 | 0.070 |
Why?
|
| Smoking | 1 | 2016 | 1452 | 0.070 |
Why?
|
| Immunoblotting | 2 | 2010 | 254 | 0.070 |
Why?
|
| Proteomics | 1 | 2009 | 246 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2010 | 232 | 0.070 |
Why?
|
| Sepsis | 1 | 2010 | 233 | 0.070 |
Why?
|
| Isoxazoles | 2 | 2008 | 22 | 0.070 |
Why?
|
| Tremor | 1 | 2006 | 16 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2005 | 73 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2006 | 272 | 0.070 |
Why?
|
| Hep G2 Cells | 2 | 2019 | 68 | 0.070 |
Why?
|
| Psychomotor Agitation | 1 | 2006 | 63 | 0.070 |
Why?
|
| Metabolic Clearance Rate | 2 | 2019 | 48 | 0.070 |
Why?
|
| Myelin Sheath | 1 | 2006 | 115 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 710 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2010 | 1553 | 0.070 |
Why?
|
| Central Nervous System | 1 | 2006 | 107 | 0.070 |
Why?
|
| Gene Expression Regulation | 3 | 2017 | 1293 | 0.070 |
Why?
|
| Ceramides | 1 | 2009 | 578 | 0.070 |
Why?
|
| Solubility | 2 | 2021 | 134 | 0.070 |
Why?
|
| Friedreich Ataxia | 1 | 2005 | 6 | 0.070 |
Why?
|
| Survival Rate | 1 | 2008 | 1056 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2017 | 294 | 0.060 |
Why?
|
| Adenosine Triphosphatases | 1 | 2005 | 83 | 0.060 |
Why?
|
| Rats | 4 | 2019 | 5300 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 196 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2005 | 99 | 0.060 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2004 | 33 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2004 | 852 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 848 | 0.060 |
Why?
|
| Protein Interaction Mapping | 2 | 2016 | 62 | 0.060 |
Why?
|
| Pregnancy | 1 | 2010 | 2334 | 0.060 |
Why?
|
| Allyl Compounds | 1 | 2004 | 29 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2010 | 2455 | 0.060 |
Why?
|
| Anticarcinogenic Agents | 1 | 2004 | 52 | 0.060 |
Why?
|
| Sulfur | 1 | 2004 | 16 | 0.060 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2019 | 111 | 0.060 |
Why?
|
| Spectrophotometry, Atomic | 1 | 2003 | 11 | 0.060 |
Why?
|
| Glutathione Synthase | 1 | 2003 | 3 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 1033 | 0.050 |
Why?
|
| Cholesterol, LDL | 2 | 2018 | 161 | 0.050 |
Why?
|
| Ku Autoantigen | 1 | 2002 | 5 | 0.050 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2002 | 5 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2002 | 88 | 0.050 |
Why?
|
| Sulfonamides | 2 | 2016 | 141 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2020 | 7029 | 0.050 |
Why?
|
| Antigens, Nuclear | 1 | 2002 | 24 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 434 | 0.050 |
Why?
|
| Dimerization | 1 | 2002 | 99 | 0.050 |
Why?
|
| Point-of-Care Testing | 1 | 2022 | 12 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2020 | 7277 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2003 | 247 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2003 | 260 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2003 | 284 | 0.050 |
Why?
|
| Parkinson Disease | 1 | 2005 | 272 | 0.050 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2022 | 60 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2022 | 93 | 0.050 |
Why?
|
| Aminooxyacetic Acid | 1 | 2002 | 2 | 0.050 |
Why?
|
| Mollusca | 1 | 2022 | 14 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2022 | 47 | 0.050 |
Why?
|
| Blood Urea Nitrogen | 1 | 2002 | 65 | 0.050 |
Why?
|
| Brazil | 1 | 2021 | 48 | 0.050 |
Why?
|
| Behavior, Animal | 2 | 2019 | 470 | 0.050 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2002 | 77 | 0.050 |
Why?
|
| Lipoproteins, LDL | 1 | 2004 | 343 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2003 | 301 | 0.050 |
Why?
|
| Models, Chemical | 1 | 2002 | 155 | 0.050 |
Why?
|
| Delayed-Action Preparations | 1 | 2021 | 120 | 0.050 |
Why?
|
| Protein Transport | 2 | 2016 | 280 | 0.050 |
Why?
|
| Tunicamycin | 1 | 2021 | 10 | 0.050 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2021 | 6 | 0.050 |
Why?
|
| Larva | 1 | 2021 | 39 | 0.050 |
Why?
|
| Emulsions | 1 | 2020 | 10 | 0.050 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2020 | 2 | 0.050 |
Why?
|
| Oxidants | 1 | 2021 | 48 | 0.050 |
Why?
|
| Yttrium Radioisotopes | 1 | 2020 | 4 | 0.050 |
Why?
|
| Necrosis | 1 | 2021 | 239 | 0.050 |
Why?
|
| Clinical Studies as Topic | 1 | 2020 | 7 | 0.050 |
Why?
|
| Nanotechnology | 1 | 2021 | 109 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 2279 | 0.050 |
Why?
|
| Risk Factors | 3 | 2019 | 5731 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2020 | 111 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2002 | 714 | 0.040 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2021 | 175 | 0.040 |
Why?
|
| Systole | 1 | 2019 | 149 | 0.040 |
Why?
|
| Transcriptome | 1 | 2021 | 164 | 0.040 |
Why?
|
| Interleukin-15 | 1 | 2019 | 66 | 0.040 |
Why?
|
| Furosemide | 1 | 2019 | 45 | 0.040 |
Why?
|
| Blood Circulation Time | 1 | 2019 | 3 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2019 | 26 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2019 | 95 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 1174 | 0.040 |
Why?
|
| Young Adult | 1 | 2010 | 5717 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 160 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 352 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 700 | 0.040 |
Why?
|
| Models, Animal | 1 | 2019 | 252 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2019 | 248 | 0.040 |
Why?
|
| Radiation Exposure | 1 | 2019 | 84 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 306 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 170 | 0.040 |
Why?
|
| Microscopy, Atomic Force | 1 | 2018 | 66 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2022 | 1753 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2018 | 112 | 0.040 |
Why?
|
| Anticholesteremic Agents | 1 | 2018 | 49 | 0.040 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 277 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2020 | 267 | 0.040 |
Why?
|
| Triglycerides | 1 | 2018 | 184 | 0.040 |
Why?
|
| Self Administration | 1 | 2019 | 419 | 0.040 |
Why?
|
| Conditioning, Operant | 1 | 2019 | 241 | 0.040 |
Why?
|
| Maytenus | 1 | 2017 | 1 | 0.040 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2018 | 114 | 0.040 |
Why?
|
| Plant Stems | 1 | 2017 | 6 | 0.040 |
Why?
|
| Niclosamide | 1 | 2017 | 2 | 0.040 |
Why?
|
| Intravitreal Injections | 1 | 2017 | 16 | 0.040 |
Why?
|
| Drug Implants | 1 | 2017 | 19 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2018 | 146 | 0.040 |
Why?
|
| 3T3-L1 Cells | 1 | 2017 | 30 | 0.040 |
Why?
|
| Chemokine CXCL2 | 1 | 2017 | 13 | 0.040 |
Why?
|
| Transcription Factor CHOP | 1 | 2017 | 28 | 0.040 |
Why?
|
| Chemokine CXCL1 | 1 | 2017 | 21 | 0.040 |
Why?
|
| Isotope Labeling | 1 | 2017 | 30 | 0.040 |
Why?
|
| A549 Cells | 1 | 2017 | 50 | 0.040 |
Why?
|
| Half-Life | 1 | 2017 | 96 | 0.040 |
Why?
|
| Receptors, Bombesin | 1 | 2016 | 3 | 0.040 |
Why?
|
| Micelles | 1 | 2017 | 43 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 103 | 0.040 |
Why?
|
| Aging | 1 | 2003 | 911 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2017 | 166 | 0.040 |
Why?
|
| Basal Ganglia | 1 | 2017 | 45 | 0.040 |
Why?
|
| Uric Acid | 1 | 2016 | 37 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2017 | 167 | 0.040 |
Why?
|
| Adult | 2 | 2016 | 21403 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2017 | 379 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2004 | 940 | 0.030 |
Why?
|
| Cytostatic Agents | 1 | 2016 | 4 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 137 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 118 | 0.030 |
Why?
|
| Etoposide | 1 | 2016 | 64 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 212 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 737 | 0.030 |
Why?
|
| Atmosphere Exposure Chambers | 1 | 2016 | 4 | 0.030 |
Why?
|
| Acrolein | 1 | 2016 | 9 | 0.030 |
Why?
|
| Quinones | 1 | 2016 | 13 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2016 | 121 | 0.030 |
Why?
|
| Hydroxylation | 1 | 2016 | 41 | 0.030 |
Why?
|
| Glycolysis | 1 | 2016 | 79 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2016 | 119 | 0.030 |
Why?
|
| Sphingolipids | 1 | 2019 | 337 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1330 | 0.030 |
Why?
|
| Peroxynitrous Acid | 1 | 2016 | 55 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2018 | 332 | 0.030 |
Why?
|
| Base Sequence | 1 | 2017 | 1015 | 0.030 |
Why?
|
| Glucose | 1 | 2017 | 307 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 2093 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 521 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 234 | 0.030 |
Why?
|
| Cues | 1 | 2019 | 654 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 504 | 0.030 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2014 | 17 | 0.030 |
Why?
|
| 3T3 Cells | 2 | 2005 | 124 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2014 | 19 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2016 | 362 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2006 | 238 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2016 | 295 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2014 | 48 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 626 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2014 | 51 | 0.030 |
Why?
|
| Alzheimer Disease | 2 | 2011 | 565 | 0.030 |
Why?
|
| Free Radical Scavengers | 1 | 2014 | 112 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1046 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 455 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 786 | 0.030 |
Why?
|
| Peroxidases | 1 | 2013 | 28 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2016 | 431 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1054 | 0.030 |
Why?
|
| Cocaine-Related Disorders | 1 | 2018 | 504 | 0.030 |
Why?
|
| Nitrogen | 1 | 2013 | 57 | 0.030 |
Why?
|
| NADP | 1 | 2013 | 39 | 0.030 |
Why?
|
| Lipid Bilayers | 1 | 2013 | 24 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 2013 | 66 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 3259 | 0.030 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2012 | 15 | 0.030 |
Why?
|
| Estrone | 1 | 2012 | 9 | 0.030 |
Why?
|
| Penile Erection | 1 | 2012 | 18 | 0.030 |
Why?
|
| Prevalence | 1 | 2016 | 1619 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2012 | 77 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 132 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2013 | 314 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 139 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2012 | 324 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 179 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2012 | 219 | 0.020 |
Why?
|
| Estradiol | 1 | 2012 | 176 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2011 | 80 | 0.020 |
Why?
|
| Mutation | 2 | 2007 | 1213 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 326 | 0.020 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2010 | 107 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2011 | 189 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2010 | 201 | 0.020 |
Why?
|
| RNA Interference | 1 | 2010 | 266 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2009 | 351 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 369 | 0.020 |
Why?
|
| Sphingosine N-Acyltransferase | 1 | 2009 | 62 | 0.020 |
Why?
|
| Lyases | 1 | 2008 | 4 | 0.020 |
Why?
|
| Kinetics | 1 | 2010 | 1047 | 0.020 |
Why?
|
| Transaminases | 1 | 2008 | 21 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2009 | 312 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2010 | 384 | 0.020 |
Why?
|
| Obesity | 1 | 2014 | 1076 | 0.020 |
Why?
|
| Sterols | 1 | 2007 | 13 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 1 | 2007 | 56 | 0.020 |
Why?
|
| United States | 1 | 2019 | 7367 | 0.020 |
Why?
|
| Cytokines | 1 | 2010 | 866 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2006 | 144 | 0.020 |
Why?
|
| Lysosomes | 1 | 2006 | 136 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 122 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2006 | 138 | 0.020 |
Why?
|
| beta-Cyclodextrins | 1 | 2005 | 5 | 0.020 |
Why?
|
| Clone Cells | 1 | 2005 | 67 | 0.020 |
Why?
|
| Neurodegenerative Diseases | 1 | 2006 | 102 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2006 | 190 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 2005 | 86 | 0.020 |
Why?
|
| Cricetulus | 1 | 2005 | 98 | 0.020 |
Why?
|
| CHO Cells | 1 | 2005 | 161 | 0.020 |
Why?
|
| Cricetinae | 1 | 2005 | 262 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 357 | 0.020 |
Why?
|
| Rabbits | 1 | 2005 | 509 | 0.020 |
Why?
|
| Leukotriene C4 | 1 | 2004 | 7 | 0.010 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2004 | 24 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2005 | 489 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2005 | 376 | 0.010 |
Why?
|
| Sulfides | 1 | 2004 | 43 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 134 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 947 | 0.010 |
Why?
|
| Biopsy | 1 | 2005 | 540 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 782 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 954 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 541 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2004 | 250 | 0.010 |
Why?
|
| Macrophages | 1 | 2006 | 647 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 2223 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1664 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2005 | 902 | 0.010 |
Why?
|